Compare PFIS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFIS | ASMB |
|---|---|---|
| Founded | 1905 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.8M | 414.7M |
| IPO Year | N/A | 2010 |
| Metric | PFIS | ASMB |
|---|---|---|
| Price | $56.88 | $26.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $56.00 | $43.40 |
| AVG Volume (30 Days) | 25.9K | ★ 98.7K |
| Earning Date | 01-30-2026 | 03-19-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 493.94 | N/A |
| EPS | ★ 5.88 | N/A |
| Revenue | ★ $187,591,000.00 | $37,191,000.00 |
| Revenue This Year | $8.45 | $33.33 |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | $9.67 | ★ N/A |
| Revenue Growth | ★ 62.85 | 31.30 |
| 52 Week Low | $38.90 | $7.75 |
| 52 Week High | $57.20 | $39.71 |
| Indicator | PFIS | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 70.46 | 41.45 |
| Support Level | $54.00 | $25.47 |
| Resistance Level | $57.02 | $27.50 |
| Average True Range (ATR) | 1.72 | 1.67 |
| MACD | 0.34 | 0.20 |
| Stochastic Oscillator | 94.80 | 28.16 |
Peoples Financial Services Corp is a bank holding company operating through its subsidiaries. The bank provides a full range of financial services. Its products and services include checking accounts, business accounts, savings accounts, loan products, money market accounts, mortgages, chip-enabled debit cards, credit card processing, and visa master card and advisory services. Its loan portfolio includes Commercial loans, which consist of commercial, commercial real estate, municipal, and other related tax-free loans; and retail loans, which include residential real estate and other consumer loans. The company mainly operates in the United States in Pennsylvania.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.